ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons"

  • Abstract Number: 2592 • 2017 ACR/ARHP Annual Meeting

    Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers

    Raj Tummala1, Tomas Rouse2, Anna Berglind2 and Linda Santiago3, 1AstraZeneca, Gaithersburg, MD, 2AstraZeneca, Gothenberg, Sweden, 3MedImmune, LLC, Mountain View, CA

    Background/Purpose: Anifrolumab is a fully human anti–interferon-ɑ receptor 1 monoclonal antibody in Phase III development as an intravenous (IV) therapeutic for systemic lupus erythematosus (SLE).…
  • Abstract Number: 2601 • 2017 ACR/ARHP Annual Meeting

    Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart

    Jie An1, Weinan Lai2,3, Joshua Woodward4, Xizhang Sun1, Lena Tanaka1, Tomikazu Sasaki5 and Keith B. Elkon6, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Medicine/Division of Rheumatology, University of Washington, Seattle, WA, 3Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China, 4Department of Microbiology, University of Washington, Seattle, WA, 5Department of Chemistry, University of Washington, Seattle, WA, 6Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA

    Background/Purpose: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres…
  • Abstract Number: 2816 • 2017 ACR/ARHP Annual Meeting

    Prediction of Connective Tissue Disease in an at-Risk Cohort Using a Novel Interferon Stimulated Gene Expression Score

    Md Yuzaiful Md Yusof1,2, Yasser M El-Sherbiny1,3, Antonios Psarras1, Elizabeth M.A. Hensor1,4, Adewonuola Alase1, Alaa Mohamed1, Miriam Wittmann1,4, Paul Emery1,4 and Edward M Vital1,4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, 4NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Prediction of connective tissue disease in an at-risk cohort using a novel interferon stimulated gene expression scoreBackground/Purpose: A period of ANA positivity and other immune…
  • Abstract Number: 2828 • 2017 ACR/ARHP Annual Meeting

    A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression

    Ilya Korsunski1, Noémie Jourde-Chiche2, Peter Gregersen3, Damien Chaussabel4, Laurent Chiche5 and Naomi I. Maria6, 1Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 2Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, 3Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Med Res, Manhasset, NY, 4Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, 5Internal medicine, Hopital europeen, Marseille, France, 6Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose: There is significant clinical and molecular heterogeneity among patients suffering from systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and primary Sjögren’s Syndrome…
  • Abstract Number: 85 • 2017 ACR/ARHP Annual Meeting

    Enhanced IFN-γ STAT1 Signaling in CD4 T Cell Populations and Attenuated IL-2 STAT5 Signaling Contribute to the Pathogenesis of Rheumatoid Arthritis (RA)

    Brandon Pope1, Vishal Sharma2, Molly Boland2, Richard Reynolds2, S. Louis Bridges Jr.3 and Chander Raman4, 1Medicine, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, 4Medicine/Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Type I (IFN-α) and type II (IFN-γ) interferons are important mediators of autoimmunity. However, there is conflicting evidence regarding the contribution of IFN-γ to…
  • Abstract Number: 860 • 2017 ACR/ARHP Annual Meeting

    Effective Treatment of Persistent Arthritis Pain Requires Co-Modulation of TNF and Type I Interferon

    Sarah Woller1, Tony Yaksh2 and Maripat Corr3, 1Anesthesiology, UCSD, La Jolla, CA, 2Anesthesiology 0818, UCSD, La Jolla, CA, 3Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA

    Background/Purpose: Pain persisting beyond the resolution or control of clinical signs of rheumatoid arthritis (RA) decreases quality of life for millions of people. Unfortunately, this…
  • Abstract Number: 866 • 2017 ACR/ARHP Annual Meeting

    Interferon-Alpha Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis

    Matthieu Ribon1,2, Katarzyna Matyja2,3, Roxane Hervé2,3, Delphine Lemeiter2,3, François Santinon2,3, Ken Tsumiyama4, Shunichi Shiozawa4, Marie-Christophe Boissier3,5,6, Natacha Bessis2,3 and Patrice Decker2,3, 1li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, 2UMR 1125, INSERM, Bobigny, France, 3Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, 4Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, 5Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France, 674 rue Marcel Cachin, INSERM, Bobigny, France

    Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
  • Abstract Number: 1656 • 2017 ACR/ARHP Annual Meeting

    Type I Interferon Drives the Dysregulation of Plasmacytoid and Myeloid Dendritic Cells in Systemic Lupus Erythematosus and Antiphospholipid Syndrome

    Lucas L. van den Hoogen1, Aridaman Pandit1, Giovanni Palla2, Marzia Rossato3, Ruth D.E. Fritsch-Stork4, Joel A.G. van Roon5 and Timothy R.D.J. Radstake1, 1Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, Laboratory of Translational Medicine, University Medical Center Utrecht, Utrecht, Netherlands, 3Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Dendritic cells (DC) are the sentinel cells of the immune system that potently activate T-cells, making them important players in the pathophysiology of systemic…
  • Abstract Number: 1663 • 2017 ACR/ARHP Annual Meeting

    De Novo Mutation in ΑCΑCΒ in Childhood Onset SLE Highlights a Novel Role As Modulator of Nucleic Acid Sensor-Driven Type I Interferon Responses

    Isaac Harley1, Hanna Schulz1, John Cambier2, Leah C. Kottyan3, John B. Harley4, V. Michael Holers5, Hermine I. Brunner6, Kristine Kuhn1, Kevin D. Deane1 and Kenneth Kaufman7, 1Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2Deparment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, 3Center for Autoimmune Genomics and Etiology (CAGE), Division of Allergy and Immunology, Cincinnati Children's Hospital, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, 6Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH

    Background/Purpose: Rare variants provide important opportunity for mechanistic insight as they carry substantial effect sizes and provide deep insight into disease etiopathogenesis. To date, several…
  • Abstract Number: 1719 • 2017 ACR/ARHP Annual Meeting

    Accelerated Wound Healing in Megakaryocyte/Platelet-Specific Fli1 Knockout Mice Due to the up-Regulated Expression of Interferon-γ

    Megumi Hirabayashi1, Yoshihide Asano2, Takashi Yamashita1, Ryosuke Saigusa1, Shunsuke Miura3, Kouki Nakamura1, Takuya Miyagawa1, Takashi Taniguchi1, Ayumi Yoshizaki1 and Shinichi Sato4, 1Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, 2Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, 3University of Tokyo, Graduate School of Medicine, Tokyo, Japan, 4Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan

    Background/Purpose: Fli1 deficiency, a potential predisposing factor of systemic sclerosis (SSc), induces SSc-like phenotypes in dermal fibroblasts, endothelial cells, keratinocytes, and macrophages. However, it is…
  • Abstract Number: 1832 • 2016 ACR/ARHP Annual Meeting

    Increased Interferon b Expression in Bone Marrow Mediates a Senescent Phenotype and Impaired Production of Immunomodulatory Factors By SLE Mesenchymal Stromal Cells

    Lin Gao1, Jennifer H. Anolik2 and R. John Looney2, 1medicine- allergy, immunology and rheumatology, University of Rochester Medical Center, Rochester, NY, 2Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Bone marrow mesenchymal stromal cells (MSCs) are multipotent stem cells that create a special microenvironment for hematopoiesis and immunity. MSCs display robust immunomodulatory properties…
  • Abstract Number: 2009 • 2016 ACR/ARHP Annual Meeting

    The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures

    JT Merrill1, R Furie2, Victoria P. Werth3,4, M Khamashta5, J Drappa6, L Wang6 and G Illei6, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Northwell Health, Great Neck, NY, 3University of Pennsylvania, Philadelphia, PA, 4Philadelphia V.A. Medical Center, Philidelphia, PA, 5Graham Hughes Lupus Research Laboratory, London, United Kingdom, 6MedImmune, Gaithersburg, MD

    Background/Purpose: The Phase IIb MUSE study (NCT01438489) of intravenous anifrolumab in 305 patients with moderate to severely active SLE (300 or 1,000 mg vs. placebo,…
  • Abstract Number: 2057 • 2016 ACR/ARHP Annual Meeting

    TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling

    Sonya Wolf1, Tamra J. Reed2, Chaim O. Jacob3 and J. Michelle Kahlenberg4, 1Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 2Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, 3Medicine/Div of Rheumatology, USC School of Medicine, Los Angeles, CA, 4Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies, immune complex deposition, elevated production of type I interferons (IFNs),…
  • Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting

    A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome

    Lucas L. van den Hoogen1, Ruth D.E. Fritsch-Stork2, Marjan A. Versnel3, Ronald H.W.M. Derksen4, Joel A.G. van Roon5,6 and Timothy R.D.J. Radstake5,6, 1Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 6Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands

    Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
  • Abstract Number: 2431 • 2016 ACR/ARHP Annual Meeting

    Characterization of Innate Immune Cells in Patients with the Interferon-Mediated Autoinflammatory Diseases Sting Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE)

    Bernadette Marrero1, Yin Liu2, Katherine R. Calvo3, Angelique Biancotto4, Yan Huang1, Adriana Almeida de Jesus1, Gina A. Montealegre Sanchez1 and Raphaela Goldbach-Mansky5, 1National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, 2Scientific Review Branch, NIAMS, NIH, Bethesda, MD, 3Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, 4Center for Human Immunology, Autoimmunity and Inflammation, NHLBI/NIH, Bethesda, MD, 5Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD

    Background/Purpose:   We recently described two rare autoinflammatory interferonopathies, STING Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology